Helix gets second US patent on DOS47

Ontario, Canada-based Helix BioPharma has been issued with its second DOS47 patent by the US Patent & Trademark Office, describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment applications. Donald Segal, chief executive of Helix, said "we believe there is significant market potential to combine DOS47-based therapeutics with certain chemotherapeutic drugs in so-called adjunct regimens because DOS47 therapy is designed to counteract tumor acidity. Tumor acidity is a property that otherwise makes it difficult for weakly basic chemotherapeutics to penetrate cancer cells and function effectively."

With the granting of this second DOS47 patent, Helix now has patent protection covering the use of targeted DOS47-based therapeutics alone and in certain combined chemotherapy applications. Moving forward, the company intends to pursue the development of DOS47 therapies for both applications.